Published

P388. Open Label Psilocybin Administration in Severely Treatment Resistant Depression

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: Biological Psychiatry
Date: 2022-04-27
Source: OpenAlex
DOI: 10.1016/j.biopsych.2022.02.624
PubMed: Unavailable

Authors

Scott Aaronson Tammy Miller Samuel Rudow MacKenzie Forbes Trisha Suppes

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Clinical Trial Randomized Controlled Trial Treatment-Resistant Depression Randomized Controlled Trial

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

P388. Open Label Psilocybin Administration in Severely Treatment Resistant Depression2022-04-27

Related papers

Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.Nature medicine · 2026-08-06 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12 Evaluating psilocybin for the management of depression: a literature reviewBritish Journal of Mental Health Nursing · 2026-08-02 Psychedelic Therapy for DepressionUnknown journal · 2026-08-11 From trial to clinic: psilocybin's efficacy in routine treatment-resistant depression.The Lancet regional health. Europe · 2026-08-01 An Open-Label Trial Protocol to Test Menstrual Cycle Effects and Tolerance to Low-Dose Psilocybin in Healthy Menstruating Persons.Pharmacology · 2026-08-10 Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10 Assessing Canadian Policy Readiness for Psychedelic-Assisted Therapy in Cancer CareUnknown journal · 2026-08-17